A phase I study of recombinant human interleukin-4 administered by the intravenous and subcutaneous route in patients with advanced cancer: immunological studies.

2.50
Hdl Handle:
http://hdl.handle.net/10541/100038
Title:
A phase I study of recombinant human interleukin-4 administered by the intravenous and subcutaneous route in patients with advanced cancer: immunological studies.
Authors:
Ghosh, Anna K; Smith, Nigel K; Prendiville, Joseph A; Thatcher, Nick; Crowther, Derek; Stern, Peter L
Abstract:
The effects of recombinant human interleukin-4 (rhu IL-4) on immunological parameters in patients receiving increasing doses of IL-4 in a Phase I trial were investigated. Peripheral blood mononuclear cells were phenotyped for a variety of lymphocyte markers, but no consistent effects were observed. However, increases in HLA Class II expression on monocytes were detected in four patients. NK and LAK activity were neither induced nor augmented by IL-4 treatment. Slight increases in proliferative responses to mitogens and cytokines were observed in some patients. The latter observations and other clinical studies suggest that a combination of IL-4 with IL-2 may be more effective in Phase II clinical trials.
Affiliation:
Cancer Research Campaign Department of Immunology, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester, United Kingdom.
Citation:
A phase I study of recombinant human interleukin-4 administered by the intravenous and subcutaneous route in patients with advanced cancer: immunological studies., 4 (3):205-11 Eur. Cytokine Netw.
Journal:
European Cytokine Network
Issue Date:
1993
URI:
http://hdl.handle.net/10541/100038
PubMed ID:
8218945
Type:
Article
Language:
en
ISSN:
1148-5493
Appears in Collections:
All Christie Publications ; All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorGhosh, Anna Ken
dc.contributor.authorSmith, Nigel Ken
dc.contributor.authorPrendiville, Joseph Aen
dc.contributor.authorThatcher, Nicken
dc.contributor.authorCrowther, Dereken
dc.contributor.authorStern, Peter Len
dc.date.accessioned2010-06-01T11:22:29Z-
dc.date.available2010-06-01T11:22:29Z-
dc.date.issued1993-
dc.identifier.citationA phase I study of recombinant human interleukin-4 administered by the intravenous and subcutaneous route in patients with advanced cancer: immunological studies., 4 (3):205-11 Eur. Cytokine Netw.en
dc.identifier.issn1148-5493-
dc.identifier.pmid8218945-
dc.identifier.urihttp://hdl.handle.net/10541/100038-
dc.description.abstractThe effects of recombinant human interleukin-4 (rhu IL-4) on immunological parameters in patients receiving increasing doses of IL-4 in a Phase I trial were investigated. Peripheral blood mononuclear cells were phenotyped for a variety of lymphocyte markers, but no consistent effects were observed. However, increases in HLA Class II expression on monocytes were detected in four patients. NK and LAK activity were neither induced nor augmented by IL-4 treatment. Slight increases in proliferative responses to mitogens and cytokines were observed in some patients. The latter observations and other clinical studies suggest that a combination of IL-4 with IL-2 may be more effective in Phase II clinical trials.en
dc.language.isoenen
dc.subjectCanceren
dc.subject.meshCell Division-
dc.subject.meshCytotoxicity, Immunologic-
dc.subject.meshHumans-
dc.subject.meshImmunophenotyping-
dc.subject.meshInjections, Intravenous-
dc.subject.meshInjections, Subcutaneous-
dc.subject.meshInterleukin-2-
dc.subject.meshInterleukin-4-
dc.subject.meshLeukocytes, Mononuclear-
dc.subject.meshLymphocytes-
dc.subject.meshMitogens-
dc.subject.meshNeoplasms-
dc.subject.meshRecombinant Proteins-
dc.titleA phase I study of recombinant human interleukin-4 administered by the intravenous and subcutaneous route in patients with advanced cancer: immunological studies.en
dc.typeArticleen
dc.contributor.departmentCancer Research Campaign Department of Immunology, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester, United Kingdom.en
dc.identifier.journalEuropean Cytokine Networken

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.